IMUGENE LIMITED — Board/Management Information 2018

Mar 27, 2018

==> picture [157 x 70] intentionally omitted <==

ASX Announcement

Leslie Chong Appointed as Managing Director

March 28, 2018: Imugene Limited (ASX: IMU), an immuno-oncology company is pleased to announce that Ms Leslie Chong has been appointed as Managing Director of the Company, effective immediately.

Immugene Executive Chairman, Mr Paul Hopper, said:

“Since her appointment as CEO, Leslie has led Imugene in an outstanding fashion. Through her leadership and tireless contribution, Imugene has successfully achieved various important milestones in both the clinical and corporate fronts. Her appointment as the company’s Managing Director recognises the value of Leslie’s strategic input as the company continues to deploy its business plan and secure sustainable growth”.

Ms Chong’s current remuneration remains unchanged after this appointment.

For further information please contact:

Imugene:

Leslie Chong Paul Hopper Chief Executive Officer Executive Chairman Tel: +61 458 040 433 Tel: +61 406 671 515

About Imugene (ASX:IMU)

Imugene (ASX:IMU) is a clinical stage immuno-oncology company headquartered in Melbourne, Australia. Its lead product is HER-Vaxx, a B Cell peptide vaccine for the treatment of gastric cancer. The company is also developing mimotope-based immunotherapies against validated and new oncology targets.

HER-Vaxx is a cancer immunotherapy designed to treat tumours that over-express the HER-2/neu receptor, such as gastric, breast, ovarian, lung and pancreatic cancers. Developed by leading scientists at the Medical University of Vienna in Austria, the peptide vaccine is constructed from several B cell epitopes of HER-2/neu. It has been shown in pre-clinical studies and in one Phase I study to stimulate a potent polyclonal antibody response to HER-2/neu, a well-known and validated cancer target.

Imugene in partnership with the Medical University of Vienna is working to discover and develop mimotope-based immunotherapies against validated and new oncology targets. This partnership has the potential to create game-changing B Cell peptide vaccines that would replace or augment conventional monoclonal antibody therapies.

For further information please visit www.imugene.com Sign up to follow @ TeamImugene on Twitter at http://www.twitter.com/TeamImugene. To follow Imugene on Facebook visit www.facebook.com/imugene

IMUGENE LIMITED Telephone +61 3 9824 5254 Fax +61 3 9822 7735 Website www.imugene.com